Press release from Companies
Published: 2013-02-11 13:10:17
WntResearch AB (WNT.ST) announces successful manufacturing of its lead product Foxy-5. WntResearch has finalized the manufacturing of GMP material for the planned Phase 1 clinical trial in 2013. The manufacturing process has been successfully scaled-up for clinical use and the Company has sufficient product to cover at least the Phase 1 clinical trial. The batch documentation and QA report are finalized and will be part of the Clinical Trial Application to the Danish Health and Medicines Authority (DHMA), which the Company plans to file in the first quarter of 2013.
CEO Nils Brünner comments: "This important milestone means that the Company has sufficient FOXY-5 GMP certified material for performing the planned Phase 1 clinical trial in 2013." For further information please contact: Nils Brünner, CEO E-mail: firstname.lastname@example.org Telephone: +45 2614 4708 About WntResearch AB WntResearch (WNT.ST) is a public company listed at the AktieTorget and is a research based Biotech Company spun out of Lund University, Sweden, founded in 2007. The focus and aim of WntResearch is to develop novel anti-metastatic therapies, in areas of unmet need, for the treatment of cancer patients. The company has two major drug development projects, Foxy-5 and Box-5. The lead project Foxy-5 is planned to enter phase 1 clinical trials in metastatic cancer in the beginning of 2013.